The Design of Inhalation Dry Powders by the Surface Modification of Drug Particles

A method for particle design to prepare a dry powder for inhalation was newly developed by the surface modification of poorly inhaled hydrophobic cohesive drug particles, e. g., pranlukast hydrate (PH, D50=2.1μm) with hydrophilic submicronized particles, e. g., colloidal silica (D50=16nm) and hydrox...

Full description

Saved in:
Bibliographic Details
Published inFuntai Kogakkaishi Vol. 33; no. 7; pp. 559 - 563
Main Authors SERIGANO, Takanori, HINO, Tomoaki, YAMAMOTO, Hiromitsu, TAKEUCHI, Hirofumi, KAWASHIMA, Yoshiaki
Format Journal Article
LanguageEnglish
Published The Society of Powder Technology, Japan 1996
Subjects
Aerosol
Colloidal Silica
Composite Particle
HPMCP Nanosphere
Inhalation Powders
Surface Modification
Online AccessGet full text

Cover

More Information
Summary:A method for particle design to prepare a dry powder for inhalation was newly developed by the surface modification of poorly inhaled hydrophobic cohesive drug particles, e. g., pranlukast hydrate (PH, D50=2.1μm) with hydrophilic submicronized particles, e. g., colloidal silica (D50=16nm) and hydroxypropylmethylcellulose phthalate (HP-55) nanospheres (D50=51.6nm) prepared by the authors. The surface modification was carried out by compounding the drug and additive particles under shear with a manually operating mortar, the particle designing equipment (a Theta composer), and by freeze drying the dispersion of the drug and additives. The surface of PH particles were modified with colloidal silica (20%) by the Theta composer and HP-55 nanospheres (2-20%) by a freeze dryer, which dramatically improved the inhalation properties of the original PH particles. In addition, surface modified PH powders with HP-55 nanospheres significantly improved the dispersibility and dissolution rate of the drug in an aqueous media which is preferable for improving the bioavailability of the drug deposited in the bronchi.
ISSN:0386-6157
1883-7239
DOI:10.4164/sptj.33.559